GLS.NSライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (8 5月 2024 @ 18:59):

Glenmark Life Sciences Limited develops, manufactures, and supplies non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India...

Stats
本日の出来高	70 290.00
平均出来高	150 080
時価総額	102.97B
EPS	INR9.69 ( 2023-10-20 )
Last Dividend	INR21.00 ( 2023-03-24 )
Next Dividend	INR0 ( N/A )
P/E	21.91
ATR14	INR1.477 (0.18%)

ボリューム相関

長: 0.12 (neutral)

短: 0.30 (neutral)

Signal:(36.874) Neutral

Glenmark Life Sciences 相関

10 最も正の相関
APCOTEXIND.NS	0.907
AMIORG.NS	0.849
RAMKY.NS	0.83
RAMRAT.NS	0.814
MAXVIL.NS	0.811
GMRINFRA.NS	0.801

10 最も負の相関
LTGILTBEES.NS	-0.87

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Glenmark Life Sciences 相関 - 通貨/商品

-0.20
( neutral )

-0.11
( neutral )

-0.24
( neutral )

-0.18
( neutral )

-0.82
( strong negative )

0.26
( neutral )

Glenmark Life Sciences 財務諸表

Annual	2023
収益:	INR22.83B
総利益:	INR12.81B (56.11 %)
EPS:	INR38.43

FY	2023
収益:	INR22.83B
総利益:	INR12.81B (56.11 %)
EPS:	INR38.43

FY	2022
収益:	INR21.61B
総利益:	INR11.47B (53.08 %)
EPS:	INR38.11

FY	2022
収益:	INR21.23B
総利益:	INR10.80B (50.88 %)
EPS:	INR35.63

Financial Reports:

No articles found.

Glenmark Life Sciences Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR10.50 (N/A)	INR0 (N/A)	INR21.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Glenmark Life Sciences Dividend Information - Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.63 - Stable (12.57%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR10.50	2021-11-22
Last Dividend	INR21.00	2023-03-24
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	3	--
Total Paid Out	INR42.00	--
Avg. Dividend % Per Year	1.99%	--
Score	4.06	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.63
Div. Directional Score	9.12	--

Next Divdend (Est)
(2024-12-18)

INR0 Estimate 0.00 %

Dividend Stability

0.07 Very Bad

Dividend Score

4.06

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2021	INR10.50	1.40%
2022	INR10.50	1.68%
2023	INR21.00	5.03%
2024	INR0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SKFINDIA.NS	Dividend Junior	2023-06-28	Annually	22	0.93%
METROBRAND.NS	Dividend Junior	2023-08-31	Semi-Annually	3	0.18%
HAL.NS	Dividend Knight	2023-08-24	Semi-Annually	6	4.33%
BCG.NS	Ex Dividend Junior	2023-09-28	Sporadic	9	0.20%
PSB.NS	No Dividend Player	2023-07-04	Sporadic	14	0.77%
KCP.NS	Dividend Junior	2023-08-10	Annually	23	0.55%
EIMCOELECO.NS	Dividend Knight	2023-06-16	Annually	23	0.80%
AGARIND.NS	Ex Dividend Junior	2023-09-08	Annually	11	0.44%
SUMICHEM.NS	Dividend Junior	2023-07-20	Annually	5	0.17%
NATCOPHARM.NS	Dividend Junior	2023-08-22	Semi-Annually	29	0.68%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.206	1.500	5.88	8.81	[0 - 0.5]
returnOnAssetsTTM	0.165	1.200	4.49	5.39	[0 - 0.3]
returnOnEquityTTM	0.204	1.500	8.85	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	4.37	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	2.64	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	0.687	1.500	7.29	10.00	[0.2 - 2]
debtRatioTTM	0.00602	-1.500	9.90	-10.00	[0 - 0.6]
interestCoverageTTM	408.14	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	6.33	2.00	7.89	10.00	[0 - 30]
freeCashFlowPerShareTTM	6.33	2.00	6.83	10.00	[0 - 20]
debtEquityRatioTTM	0.00735	-1.500	9.97	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.561	1.000	3.98	3.98	[0.2 - 0.8]
operatingProfitMarginTTM	0.276	1.000	6.47	6.47	[0.1 - 0.6]
cashFlowToDebtRatioTTM	4.54	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.801	0.800	7.99	6.39	[0.5 - 2]
Total Score				12.61

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	21.48	1.000	7.93	0	[1 - 100]
returnOnEquityTTM	0.204	2.50	9.26	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	6.33	2.00	7.89	10.00	[0 - 30]
dividendYielPercentageTTM	2.73	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.33	2.00	7.89	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	2.32	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0341	1.000	-1.648	0	[0.1 - 0.5]
Total Score				5.63

Glenmark Life Sciences

Glenmark Life Sciences Limited develops, manufactures, and supplies non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers Olmesartan, Amiodarone, Telmisartan, Perindopril, Rosuvastatin, and Cilostazol for cardiovascular diseases; Oxcarbazepine, Zonisamide, Topiramate, Bupropion, Ropinirole, Riluzole, and Lacosamide for central nervous system diseases; Glimepiride, Teneligliptin, Vildagliptin, and Linagliptin for diabetes; and Etoricoxib and Lornoxicam for pain management. It also provides Atovaquone, Voriconazole, Mirabegron, Desloratadine, Esomeprazole Magnesium, Adapalene, and Fluconazole gastro-intestinal disorders, anti-infective, respiratory, anti-emetic, and other therapeutic areas. In addition, the company offers contract development and manufacturing services to a range of multinational pharmaceutical and specialty pharmaceutical companies. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was incorporated in 2011 and is based in Mumbai, India. Glenmark Life Sciences Limited is a subsidiary of Glenmark Pharmaceuticals Limited.